Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹3,113 Cr
Revenue (TTM)
₹2,522 Cr
Net Profit (TTM)
₹203 Cr
ROE
12.7 %
ROCE
13.1 %
P/E Ratio
15.4
P/B Ratio
2.1
Industry P/E
33.39
EV/EBITDA
11.8
Div. Yield
0.3 %
Debt to Equity
0.4
Book Value
₹165.3
EPS
₹22.2
Face value
10
Shares outstanding
91,270,000
CFO
₹1,733.84 Cr
EBITDA
₹2,742.09 Cr
Net Profit
₹1,455.42 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aarti Drugs
| -17.1 | -8.9 | -11.4 | 2.4 | 2.5 | -12.9 | 11.0 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aarti Drugs
| -9.6 | -7.1 | 6.3 | -15.6 | -25.9 | 376.5 | 0.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aarti Drugs
|
341.2 | 3,112.8 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.4 | 2.1 |
| 942.0 | 11,539.7 | 2,512.3 | 543.7 | 28.3 | 19.3 | 21.2 | 3.6 | |
| 383.3 | 6,657.6 | 1,053.1 | 293.6 | 32.3 | 24.6 | 22.7 | 5.1 | |
| 1,142.9 | 11,940.9 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.2 | 6.3 | |
| 1,531.5 | 29,049.9 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.4 | 5.8 | |
| 285.1 | 3,101.7 | 159.3 | 47.8 | 39.0 | 18.6 | 64.9 | 11.2 | |
| 12,413.0 | 15,918.8 | 1,575.1 | 179.1 | 14.9 | 11.4 | 88.9 | 9.6 | |
| 1,925.6 | 3,162.1 | 673.7 | 202.6 | 17.6 | 19.4 | 15.6 | 5.5 | |
| 750.0 | 3,444.8 | 588.5 | 102.9 | 22.1 | 12.7 | 33.9 | 4.1 | |
| 138.1 | 3,636.7 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 5.5 |
2 min read•By Vikas Vardhan
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac,... celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India. Read more
Incorporated
1984
Chairman
Prakash M Patil
Managing Director
Rashesh C Gogri
Group
Aarti
Headquarters
Thane, Maharashtra
Website
Looking for more details about Aarti Drugs Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Aarti Drugs Ltd is ₹341.15 (NSE) and ₹341.05 (BSE) as of 18-Mar-2026 IST. Aarti Drugs Ltd has given a return of 2.47% in the last 3 years.
The P/E ratio of Aarti Drugs Ltd is 15.37 times as on 18-Mar-2026, a 54 discount to its peers’ median range of 33.39 times.
The P/B ratio of Aarti Drugs Ltd is 2.06 times as on 18-Mar-2026, a 5 discount to its peers’ median range of 2.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.44
|
2.27
|
|
2024
|
23.27
|
3.11
|
|
2023
|
18.81
|
2.62
|
|
2022
|
19.37
|
3.83
|
|
2021
|
23.09
|
7.09
|
The 52-week high and low of Aarti Drugs Ltd are Rs 564.05 and Rs 312.00 as of 19-Mar-2026.
Aarti Drugs Ltd has a market capitalisation of ₹ 3,113 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aarti Drugs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹7.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.